Phase II, multicenter, randomized, parallel, three-arm, placebo-controlled study to evaluate the efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction (=45%) after myocardial infarction (HF- REVERT)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: CARDIOR PHARMACEUTICALS GMBH
- Phase: II
- Execution start: 04/04/2022
- End of execution: 30/09/2024
- PI: JESUS GABRIEL SANCHEZ RAMOS